This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Karo Pharma Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

-46.5%

Wachstumsrate der Gewinne

-52.9%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie30.5%
Wachstumsrate der Einnahmen29.8%
Eigenkapitalrendite-2.3%
Netto-Marge-5.5%
Letzte Ertragsaktualisierung30 Jun 2022

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Karo Pharma (STO:KARO) Has No Shortage Of Debt

Oct 14
Karo Pharma (STO:KARO) Has No Shortage Of Debt

Is Karo Pharma (STO:KARO) A Risky Investment?

Jul 10
Is Karo Pharma (STO:KARO) A Risky Investment?

Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt

Mar 23
Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt

Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality

Feb 24
Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality

Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?

Feb 22
Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?

Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?

Feb 01
Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?

Aufschlüsselung der Einnahmen und Ausgaben

Wie Karo Pharma Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

OM:KARO Einnahmen, Ausgaben und Erträge (SEK Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Jun 223,466-1901,9350
31 Mar 223,231-1411,7450
31 Dec 212,961-171,5130
30 Sep 212,921631,3380
30 Jun 212,86121,4040
31 Mar 212,802491,3030
31 Dec 202,883821,3510
30 Sep 202,811861,1810
30 Jun 202,575871,0160
31 Mar 202,274558420
31 Dec 191,90196810
30 Sep 191,715606730
30 Jun 191,6671176110
31 Mar 191,7696505810
31 Dec 181,6156575211
30 Sep 181,3915954452
30 Jun 181,1325513692
31 Mar 18785402883
31 Dec 17658152424
30 Sep 175151411783
30 Jun 174631331585
31 Mar 174041141535
31 Dec 16347961415
30 Sep 16308-2013010
30 Jun 16232-4111013
31 Mar 16151-607729
31 Dec 1569-785435

Qualität der Erträge: KARO is currently unprofitable.

Wachsende Gewinnspanne: KARO is currently unprofitable.


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: KARO is unprofitable, and losses have increased over the past 5 years at a rate of 46.5% per year.

Beschleunigtes Wachstum: Unable to compare KARO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Erträge im Vergleich zur Industrie: KARO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.2%).


Eigenkapitalrendite

Hohe Eigenkapitalrendite: KARO has a negative Return on Equity (-2.3%), as it is currently unprofitable.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren